Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-zeta chimeric receptor.
Therapies that Ag-specifically target pathologic T lymphocytes responsible for multiple sclerosis (MS) and other autoimmune diseases would be expected to have improved therapeutic indices compared with Ag-nonspecific therapies. We have developed a cellular immunotherapy that uses chimeric receptors...
Main Authors: | Moisini, I, Nguyen, P, Fugger, L, Geiger, T |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.
by: Kort, J, et al.
Published: (2006) -
Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
by: Fridkis-Hareli, M, et al.
Published: (2001) -
Adhesion Process of Biomimetic Myelin Membranes Triggered by Myelin Basic Protein
by: Benjamin Krugmann, et al.
Published: (2021-05-01) -
Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes
by: Monica Casucci, Attilio Bondanza
Published: (2011-01-01) -
Myelin lipid metabolism and its role in myelination and myelin maintenance
by: Joseph A. Barnes-Vélez, et al.
Published: (2023-01-01)